Clinical experience
EfficacyThe result of a randomised controlled multicentre phase III trial (evidence level I) showed that by using Gliolan®, neurosurgeons achieved 64% complete resections compared to only 38% among the control group.1 |
Reference
1. https://www.ema.europa.eu/en/documents/scientific-discussion/gliolan-epar-scientific-discussion_en.pdf